This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BMS-512148, dapagliflozin, Forxiga (EU), Edistride (EU), Oxra (India)
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The SGLT2 transporter protein is located only in the kidney, where it normally reabsorbs glucose from urine while waste products are filtered out. Patients with Type 2 diabetes continue to reabsorb glucose from the urine, even though this process contributes to high blood glucose levels, or hyperglycemia. Dapagliflozin has a mechanism of action that blocks re-absorption of glucose from urine in patients with Type 2 diabetes. Inhibiting SGLT2 activity decreases re-absorption of glucose by the kidney,helping to improve glucose control in patients with Type 2 diabetes.
A fixed dose combination of saxagliptin and dapagliflozin, known as SaxaDapa FDC, is also in clinical development.
Revenue splits are BioMedTracker estimates.
Bristol-Myers Squibb and AstraZeneca
In January 2007, Bristol-Myers Squibb and AstraZeneca announced a collaboration to develop and commercialize saxagliptin and dapagliflozin, both discovered by Bristol-Myers Squibb. Terms of the agreements include an upfront payment of $100 million by AstraZeneca to Bristol-Myers Squibb. The companies have agreed upon initial development plans for the two compounds. From 2007 through 2009, the majority of development costs will be funded by AstraZeneca. Any additional development costs will be shared equally.
Bristol-Myers Squibb may also receive additional payments of up to $650 million based on development and regulatory milestones for the two compounds. In addition, potential sales milestones up to $300 million per product are also possible. The companies will jointly develop the clinical and marketing strategy of the compounds, and post-launch will sharecommercialization...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company Ono Pharmaceutical Company, Ltd. Sun Pharmaceutical Industries Ltd.
Additional information available to subscribers only: